EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Course of Portal Hypertension and Its Prognostic Impact After Liver Transplantation

Nina Dominik iD, Petra Dinjar Kujundzic iD, Sandra Lovrekovic iD, Hrvoje Premec iD, Felix Kristandl, Lorenz Balcar iD, Maja Mijic iD, Milos Lalovac, Benedikt Silvester Hofer iD, Lukas Hartl iD, Christian Sebesta iD, Georg Kramer iD und 9 weitere

United European Gastroenterology Journal · 2026

DOI: 10.1002/ueg2.70268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2026. Verfasst von Nina Dominik und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Hypertension, Portal, Liver Transplantation, Postoperative Complications, End Stage Liver Disease. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While portal hypertension (PH) typically resolves after liver transplantation (LT), persistence of PH may affect post‐transplant outcomes. We assessed the evolution of PH after LT and its impact on adverse outcomes.

Methods

We recorded clinical, laboratory, and imaging parameters of LT recipients between 2016 and 2022 in Vienna and Zagreb. Persistent features of CSPH were defined as the presence of portosystemic collaterals, platelet count (PLT) ≤ 110 G/L, and/or splenomegaly (≥ 13 cm). PH‐related clinical events were defined as variceal bleeding, ascites requiring intervention, hepatic hydrothorax, portal vein thrombosis, or liver‐related death within 12 months post‐LT. Post‐LT outcomes were analyzed using landmark Cox regression for 3 months post‐LT.

Results

Of 645 LT recipients (76% male, median age 59 years) listed with a median MELD of 15 points and PLT of 99 G/L, features of CSPH were present in 537 (83.3%) at baseline. At year 1 after LT, MELD improved to 9 (IQR 7–12), PLT increased to 160 G/L (IQR 120–207), and features of CSPH persisted in 251/453 classifiable patients (55.4%). PH events occurred in 75 (11.6%) and 84 (13%) deaths. In a landmark analysis from 3 months post‐LT ( n = 521, 29 deaths), persistent thrombocytopenia (< 110 G/L) at M3 independently predicted mortality (aHR 2.31, 95% CI 1.01–5.30, p = 0.048) after adjustment for MELD, age, CRP, and pre‐LT TIPS.

Conclusions

While PH improves after LT, features of CSPH persisted in 55% of classifiable patients and PH‐related clinical events occurred in 11.6% within the first year after LT. Persistent thrombocytopenia (< 110 G/L) at 3 months post‐LT independently predicted post‐LT mortality (aHR 2.31, 95% CI 1.01–5.30, p = 0.048).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PortalLiver TransplantationPostoperative ComplicationsEnd Stage Liver DiseaseHumansMalePrognosisFemaleMiddle AgedPlatelet CountEsophageal and Gastric VaricesRetrospective StudiesGastrointestinal HemorrhageAscitesAgedThrombocytopeniaSplenomegaly

Stichwörter der Autor:innen

liver transplantationplatelet dynamicsportal hypertensionpost‐transplant outcomesthrombocytopenia

Autor:innen und Institutionen

  • Department of Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
  • Department of Medicine III, Division of Gastroenterology and Hepatology, Vienna Hepatic Hemodynamic Lab, Medical University of Vienna, Vienna, Austria.
  • Clinical Research Group MOTION, Medical University of Vienna, Vienna, Austria.
  • Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, Zagreb, Croatia.
  • Department of Gastroenterology and Hepatology, School of Medicine, University Hospital Merkur, University of Zagreb, Zagreb, Croatia.
  • Department of Surgery, Division of Transplantation, University Hospital Merkur, Zagreb, Croatia.

ORCID-Profile: Nina Dominik, Petra Dinjar Kujundzic, Sandra Lovrekovic, Hrvoje Premec, Lorenz Balcar, Maja Mijic, Benedikt Silvester Hofer, Lukas Hartl, Christian Sebesta, Georg Kramer, Paul Thöne, Mattias Mandorfer, Georg Györi, Gabriela Berlakovich, Tajana Filipec Kanizaj, Thomas Reiberger

Zitieren

APA

Dominik, N., Dinjar Kujundzic, P., Lovrekovic, S., Premec, H., Kristandl, F., Balcar, L., Mijic, M., Lalovac, M., Hofer, B. S., Hartl, L., Sebesta, C., Kramer, G., Thöne, P., Mandorfer, M., Trauner, M., Mikulic, D., Jadrijevic, S., Györi, G., Berlakovich, G., …, & Reiberger, T. (2026). Course of Portal Hypertension and Its Prognostic Impact After Liver Transplantation. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.70268

Vancouver

Dominik N, Dinjar Kujundzic P, Lovrekovic S, Premec H, Kristandl F, Balcar L, et al. Course of Portal Hypertension and Its Prognostic Impact After Liver Transplantation. United European Gastroenterology Journal. 2026. doi:10.1002/ueg2.70268

BibTeX
@article{Dominik2026,
  author = {Dominik, Nina and Dinjar Kujundzic, Petra and Lovrekovic, Sandra and Premec, Hrvoje and Kristandl, Felix and Balcar, Lorenz and Mijic, Maja and Lalovac, Milos and Hofer, Benedikt Silvester and Hartl, Lukas and Sebesta, Christian and Kramer, Georg and Thöne, Paul and Mandorfer, Mattias and Trauner, Michael and Mikulic, Danko and Jadrijevic, Stipislav and Györi, Georg and Berlakovich, Gabriela and Filipec Kanizaj, Tajana and Reiberger, Thomas},
  title = {Course of Portal Hypertension and Its Prognostic Impact After Liver Transplantation},
  journal = {United European Gastroenterology Journal},
  year = {2026},
  doi = {10.1002/ueg2.70268}
}
Kostenlos starten →